These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

347 related items for PubMed ID: 17445798

  • 1. Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats.
    Tronci E, Simola N, Borsini F, Schintu N, Frau L, Carminati P, Morelli M.
    Eur J Pharmacol; 2007 Jul 02; 566(1-3):94-102. PubMed ID: 17445798
    [Abstract] [Full Text] [Related]

  • 2. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets.
    Rose S, Jackson MJ, Smith LA, Stockwell K, Johnson L, Carminati P, Jenner P.
    Eur J Pharmacol; 2006 Sep 28; 546(1-3):82-7. PubMed ID: 16925991
    [Abstract] [Full Text] [Related]

  • 3. Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats.
    Carta AR, Pinna A, Cauli O, Morelli M.
    Synapse; 2002 Jun 01; 44(3):166-74. PubMed ID: 11954048
    [Abstract] [Full Text] [Related]

  • 4. The novel adenosine A2a antagonist ST1535 potentiates the effects of a threshold dose of l-dopa in unilaterally 6-OHDA-lesioned rats.
    Rose S, Ramsay Croft N, Jenner P.
    Brain Res; 2007 Feb 16; 1133(1):110-4. PubMed ID: 17196564
    [Abstract] [Full Text] [Related]

  • 5. A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug.
    Pinna A, Tronci E, Schintu N, Simola N, Volpini R, Pontis S, Cristalli G, Morelli M.
    Neuropharmacology; 2010 Mar 16; 58(3):613-23. PubMed ID: 19951715
    [Abstract] [Full Text] [Related]

  • 6. Blockade of A2A receptors plus l-DOPA after nigrostriatal lesion results in GAD67 mRNA changes different from l-DOPA alone in the rat globus pallidus and substantia nigra reticulata.
    Carta AR, Tabrizi MA, Baraldi PG, Pinna A, Pala P, Morelli M.
    Exp Neurol; 2003 Dec 16; 184(2):679-87. PubMed ID: 14769359
    [Abstract] [Full Text] [Related]

  • 7. Animal models of Parkinson׳s disease: Effects of two adenosine A2A receptor antagonists ST4206 and ST3932, metabolites of 2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine (ST1535).
    Stasi MA, Minetti P, Lombardo K, Riccioni T, Caprioli A, Vertechy M, Di Serio S, Pace S, Borsini F.
    Eur J Pharmacol; 2015 Aug 15; 761():353-61. PubMed ID: 25936513
    [Abstract] [Full Text] [Related]

  • 8. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease.
    Agnati LF, Leo G, Vergoni AV, Martínez E, Hockemeyer J, Lluis C, Franco R, Fuxe K, Ferré S.
    Brain Res Bull; 2004 Aug 30; 64(2):155-64. PubMed ID: 15342103
    [Abstract] [Full Text] [Related]

  • 9. Motor stimulant effects of the adenosine A2A receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats.
    Pinna A, Fenu S, Morelli M.
    Synapse; 2001 Mar 01; 39(3):233-8. PubMed ID: 11284438
    [Abstract] [Full Text] [Related]

  • 10. Behavioural and neurochemical characterization of the adenosine A2A receptor antagonist ST1535.
    Galluzzo M, Pintor A, Pèzzola A, Grieco R, Borsini F, Popoli P.
    Eur J Pharmacol; 2008 Jan 28; 579(1-3):149-52. PubMed ID: 18036583
    [Abstract] [Full Text] [Related]

  • 11. Modulation of the motor response to dopaminergic drugs in a parkinsonian model of combined dopaminergic and noradrenergic degeneration.
    Pérez V, Sosti V, Rubio A, Barbanoj M, Rodríguez-Alvarez J, Kulisevsky J.
    Eur J Pharmacol; 2007 Dec 08; 576(1-3):83-90. PubMed ID: 17888901
    [Abstract] [Full Text] [Related]

  • 12. Characterization of enhanced behavioral responses to L-DOPA following repeated administration in the 6-hydroxydopamine-lesioned rat model of Parkinson's disease.
    Henry B, Crossman AR, Brotchie JM.
    Exp Neurol; 1998 Jun 08; 151(2):334-42. PubMed ID: 9628768
    [Abstract] [Full Text] [Related]

  • 13. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
    Carta AR, Frau L, Pinna A, Pontis S, Simola N, Schintu N, Morelli M.
    Synapse; 2008 Jul 08; 62(7):524-33. PubMed ID: 18435422
    [Abstract] [Full Text] [Related]

  • 14. Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats.
    Carta AR, Pinna A, Tronci E, Morelli M.
    Neurology; 2003 Dec 09; 61(11 Suppl 6):S39-43. PubMed ID: 14663008
    [Abstract] [Full Text] [Related]

  • 15. New adenosine A2A receptor antagonists: actions on Parkinson's disease models.
    Pinna A, Volpini R, Cristalli G, Morelli M.
    Eur J Pharmacol; 2005 Apr 11; 512(2-3):157-64. PubMed ID: 15840400
    [Abstract] [Full Text] [Related]

  • 16. Different responsiveness of striatonigral and striatopallidal neurons to L-DOPA after a subchronic intermittent L-DOPA treatment.
    Carta AR, Tronci E, Pinna A, Morelli M.
    Eur J Neurosci; 2005 Mar 11; 21(5):1196-204. PubMed ID: 15813929
    [Abstract] [Full Text] [Related]

  • 17. Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease.
    Pinna A, Pontis S, Borsini F, Morelli M.
    Synapse; 2007 Aug 11; 61(8):606-14. PubMed ID: 17476684
    [Abstract] [Full Text] [Related]

  • 18. Upregulation of striatal adenosine A2A receptor mRNA in 6-hydroxydopamine-lesioned rats intermittently treated with L-DOPA.
    Tomiyama M, Kimura T, Maeda T, Tanaka H, Kannari K, Baba M.
    Synapse; 2004 Jun 01; 52(3):218-22. PubMed ID: 15065221
    [Abstract] [Full Text] [Related]

  • 19. L-DOPA-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA.
    Cenci MA, Lee CS, Björklund A.
    Eur J Neurosci; 1998 Aug 01; 10(8):2694-706. PubMed ID: 9767399
    [Abstract] [Full Text] [Related]

  • 20. Synergistic effect of SCH 58261, an adenosine A2A receptor antagonist, and L-DOPA on the reserpine-induced muscle rigidity in rats.
    Wardas J.
    Pol J Pharmacol; 2003 Aug 01; 55(2):155-64. PubMed ID: 12926542
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.